Background: Although there are many advances in the diagnosis and resuscitation of patients with cardiogenic shock, the mortality rate is still high, especially for patients with cardiogenic shock due to complications of acute myocardial infarction, the mortality rate can be up to 50 - 70%. 

Objective: "Evaluate the effectiveness of clinical, subclinical and complications of V-A ECMO in patients with cardiogenic shock". 

Method: descriptive analysis of patients diagnosed with cardiogenic shock supported by V-A ECMO revascularization from October 2018 and June 2020. 

Results: There were 23 patients hospitalized for cardiogenic shock, they have used the V-A ECMO. The mean age was 53,5±17,6, the minimum age was 13, the oldest was 76. The highest rate of causes leading to cardiogenic shock was myocardial infarction (47.8%) and myocarditis (39.1%); besides, cardiogenic shock patients with thyroid storm also appeared in the study. The shortest hospital stay time was 3.5 day and the longest treatment time is 32 days. There were 15 patients alive, accounting for 65.2%, 8 patients died, accounting for 35.8%. The percentage of patients living in the group of myocarditis reached the highest rate. Common complications in patients supported by V-A ECMO are left ventricular volume overload and infection; the rate of left ventricular overload accounted for 47.8%; 100% of patients developed infection during V-A ECMO. Methods to reduce left ventricular pressure include: use of aortic counterpulsation balloon (IABP), atrial septal rupture, and left ventricular drainage through the aortic valve(TAVC). the proportion of patients with temporary pacemaker implantation accounted for 43.5%, but during the follow-up period, all cases showed that the pacing spide lost conduction capacity. Conclusion: V-A ECMO is a treatment option for life-threatening cardiogenic shock that has not responded to standard therapy.